- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05035173
The LYSA (Linking You to Support and Advice) Trial (LYSA)
Women's Cancer Survivorship: The LYSA (Linking You to Support and Advice) Trial
Study Overview
Status
Detailed Description
Study Design: Complex interventional study. Specific Aims: To evaluate the feasibility of introducing a women's malignancy survivorship clinic in Ireland incorporating symptom management through electronic Patient Reported Outcomes (ePROs) collection (complex intervention) into routine follow-up care in patients with early-stage HR-positive breast and gynecologic cancer post-primary therapy.
Sampling Method: Randomized Control Design (Parallel Arms). Sample Size: 200.
Entry Criteria: Women with early-stage breast/gynecologic cancer within 12 months of completion of primary curative therapy:
- Breast cancer: Stage I-III hormone receptor-positive (defined as estrogen receptor and/or progesterone receptor ≥ 1%) and HER2-negative per ASCO-CAP guidelines on or recommended to commence adjuvant endocrine therapy during the study period.
- Cervical cancer: Stage I to III treated with curative intent.
- Endometrial cancer: treated with curative intent adjuvant radiotherapy +/- chemotherapy
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Cork, Ireland, T12 DFK4
- Cork University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Women aged > or = 18 years.
- Ability to read and understand English.
- Access to internet.
Early-stage breast/gynaecologic cancer within 12 months of completion of primary curative therapy:
- Breast cancer: Stage I-III hormone receptor-positive (defined as estrogen receptor and/or progesterone receptor ≥ 1%) and HER2-negative per ASCO-CAP guidelines on or recommended to commence adjuvant endocrine therapy during the study period.
- Cervical cancer: Stage I to III treated with curative intent.
- Endometrial cancer: treated with curative intent adjuvant radiotherapy +/- chemotherapy
Exclusion Criteria:
- Patients who are not treated with curative intent as above.
- Patients with premalignant disease.
- Persons who, in the opinion of the researcher or supervising clinician, are unable to cooperate adequately with the study protocol.
- Recent (within 12 months) participation in a study/programme involving a lifestyle intervention (e.g diet, exercise, survivorship). Note: Per discretion of PI as to whether may impact the outcome of this study intervention.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intervention Arm
Participants will have available the services offered by the Women's Cancer Survivorship Clinic and will undertake electronic Patient Reported Outcomes at baseline, 2, 4, 6, 8, 10, 12 months (end of the study).
|
Patients will visit in person the Survivorship Clinic at the baseline and end of the study (12-month) at the ORCHID center in the Cork University Hospital (Cork, Ireland). During these visits, baseline and end of the study assessments will be made. Patients will receive routine standard information, a care plan and resources about survivorship at the baseline visit. Patients will receive a Survivorship Personal Treatment Plan by the nurse from the Women's Health Initiative Survivorship Clinic according to the results from the baseline ePROs. In addition to that, each 2 months for a period of 12 months, the patient will be answering ePROs. The nurse will undertake an intervention when needed based as per the Trigger system (developed form ePROs responses) or clinical judgement. - ePRO Symptom Survey Instrument (nurse questions): A core list of symptoms/adverse events that are identified including gastrointestinal, attention/memory, pain, fatigue and insomnia, mood-emotional distress/depression, anxiety, fear of cancer recurrence, gynaecological, urinary, sexual issues, hot flashes.
Other Names:
Patients will receive Diet Education and Personalised Nutrition Counselling by the dietitian from the Women's Health Initiative Survivorship Clinic at the baseline. In addition to that, each 2 months for a period of 12 months, the patient will be answering ePROs. The dietitian will undertake an intervention when needed as per the Trigger system (developed form ePROs responses) or clinical judgement. - ePRO Symptom Survey Instrument (diet questions): nutritional risk (lack of appetite; worry regarding weight loss; worry regarding weight gain), weight, and exercise.
Other Names:
|
Active Comparator: Control Arm
Participants will attend a baseline and end of the study visit (12-month time point) to the Women's Cancer Survivorship Clinic to undertake the baseline and complete end of study assessments.
They will complete ePRO at baseline and at 12 months.
They will have usual follow up care over the 12 month period of the study.
Where participants in the control arm contact the Survivorship team for clinical or other advice, they will be referred to the usual care pathway.
|
Patients will visit in person the Survivorship Clinic at the baseline and end of the study (12-month) at the ORCHID center in the Cork University Hospital (Cork, Ireland). During these visits, baseline and end of the study assessments will be made. Patients will receive routine standard information, a care plan and resources about survivorship at the baseline visit. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of patients enrolled in the clinic.
Time Frame: At the baseline
|
Number of patients who were eligible and accepted to participate in the study.
This will be recorded in the electronic Case Report Forms (eCRF).
|
At the baseline
|
Reasons for not enrolling to the study.
Time Frame: At the baseline
|
The reasons for not enrolling will be asked to the patient considering and clusters of option groups will be done.This will be recorded in the electronic Case Report Forms (eCRF).
|
At the baseline
|
Reasons for not completing the intervention (drop out).
Time Frame: During the study period (12-month)
|
Patients will be contacted to ask about the reasons for not completing the intervention.
This will be recorded in the electronic Case Report Forms (eCRF).
|
During the study period (12-month)
|
Percentage of adherence to the intervention completing ePROs surveys
Time Frame: Baseline, each 2 months till end intervention (12 months)
|
Number of enrolled patients who complete the baseline and follow-up ePRO surveys.
This will be recorded in the ePROs.
|
Baseline, each 2 months till end intervention (12 months)
|
Number of patients who partake in healthcare professional consultations after ePRO data triggers.
Time Frame: Baseline, each 2 months till end intervention (12 months)
|
A trigger system with the ePRO measurements has been developed to assess symptoms deterioration that will require that the nurse or Dietitian contact the patient.
This will be recorded in the electronic Case Report Forms (eCRF).
|
Baseline, each 2 months till end intervention (12 months)
|
Average consultation time in the Womens Survivorship Clinic.
Time Frame: Baseline, each 2 months till end intervention (12 months)
|
Time spent by the Nurse, the Dietitian and other Health Care Professionals (HCP) from the Women Survivorship Clinic during consultation will be collected.
This will be recorded in the electronic Case Report Forms (eCRF).
|
Baseline, each 2 months till end intervention (12 months)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from Baseline in cancer-related symptoms scores assessed by Patient-Reported Outcomes.
Time Frame: Both arms at the baseline and at the end of the study (12-month); intervention arm month 2, 4, 6, 8, 10
|
The cancer-related symptoms items will be assessed by the validated Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE™) item library and Patient-Reported Outcomes Measurement Information System (PROMIS) item library.
|
Both arms at the baseline and at the end of the study (12-month); intervention arm month 2, 4, 6, 8, 10
|
Change from Baseline in Health related-Quality of Life Questionnaire (QLQ) scores assessed by European Organization for the Research and Treatment of Cancer (EORTC).
Time Frame: Both arms at the baseline and at the end of the intervention (12-month)
|
All patients will answer at the baseline and at the end of the intervention EORTC QLQ-C30 (30 items).
The scoring will be performed according to the EORTC scoring manual.
All scores will be linearly transformed to a 0 to 100 scale.
A high or healthy level of functioning represents a high functional score.
|
Both arms at the baseline and at the end of the intervention (12-month)
|
Change from Baseline in Health related-Quality of Life Questionnaire (QLQ) Breast Cancer Module scores assessed by European Organization for the Research and Treatment of Cancer (EORTC).
Time Frame: Both arms at the baseline and at the end of the intervention (12-month)
|
Cohort of patients who had breast cancer will answer at the baseline and at the end of the intervention EORTC QLQ Breast Cancer Module (BR23).
The scoring will be performed according to the EORTC scoring manual.
All scores will be linearly transformed to a 0 to 100 scale.
A high or healthy level of functioning represents a high functional score.
|
Both arms at the baseline and at the end of the intervention (12-month)
|
Change from Baseline in Health related-Quality of Life Questionnaire (QLQ) Cervical Cancer Module scores assessed by European Organization for the Research and Treatment of Cancer (EORTC).
Time Frame: Both arms at the baseline and at the end of the intervention (12-month)
|
Cohort of patients who had cervical cancer will answer at the baseline and at the end of the intervention EORTC QLQ Cervical Cancer Module (CX24).
The scoring will be performed according to the EORTC scoring manual.
All scores will be linearly transformed to a 0 to 100 scale.
A high or healthy level of functioning represents a high functional score.
|
Both arms at the baseline and at the end of the intervention (12-month)
|
Change from Baseline in Health related-Quality of Life Questionnaire (QLQ) Endometrial Cancer Module scores assessed by European Organization for the Research and Treatment of Cancer (EORTC).
Time Frame: Both arms at the baseline and at the end of the intervention (12-month)
|
Cohort of patients who had endometrial cancer will answer at the baseline and at the end of the intervention EORTC QLQ Endometrial Cancer Module (EN24).
The scoring will be performed according to the EORTC scoring manual.
All scores will be linearly transformed to a 0 to 100 scale.
A high or healthy level of functioning represents a high functional score.
|
Both arms at the baseline and at the end of the intervention (12-month)
|
Change from Baseline in EuroQol 5-Level 5-Dimensions quality-adjusted life-year version (EQ-5D-5L-QALY) scores.
Time Frame: Both arms at the baseline and at the end of the intervention (12-month)
|
All patients will answer the EQ-5D-5L-QALY at the baseline and at the end of the intervention.
A high score represents high functionality problems.
|
Both arms at the baseline and at the end of the intervention (12-month)
|
Change from Baseline in Appraisal Self-Care Agency-R scores (15 items).
Time Frame: Both arms at the baseline and at the end of the intervention (12-month)
|
All patients will answer at the baseline and at the end of the intervention the Appraisal Self-Care Agency-R (15 items).
The higher the score, the better the self-care agency
|
Both arms at the baseline and at the end of the intervention (12-month)
|
Change from Baseline in adjuvant endocrine therapy medication adherence.
Time Frame: Both arms at the baseline and at the end of the study (12-month); intervention arm month 2, 4, 6, 8, 10
|
All patients will self-report their adherence at the baseline and at the end of the study.
The intervention arm will be asked about it every 2 months.
|
Both arms at the baseline and at the end of the study (12-month); intervention arm month 2, 4, 6, 8, 10
|
Assessment of Usability and Satisfaction of the survivorship clinic will be assessed by the Usability and Satisfaction Scale (Lewis, 1995).
Time Frame: Intervention arms at the end of the intervention (12-month)
|
Patients in the intervention arm will complete the Usability and Satisfaction Scale (Lewis, 1995) at the end of the intervention.
The higher the score, the better usability and satisfaction from the participant.
|
Intervention arms at the end of the intervention (12-month)
|
Experience and opinions from patients, HCP and wider stakeholders about the Women Survivorship Study including the clinic.
Time Frame: Intervention arms at the end of the intervention (12-month)
|
Qualitative data collection will be done via Interviews/Focus Groups at the end of the intervention.
|
Intervention arms at the end of the intervention (12-month)
|
Number of resources used by each patient with a cancer related symptom to evaluate the economic impact.
Time Frame: Both arms at the end of the intervention (12-month)
|
The main sources from which this data will be collected include: patient hospital record forms, case report forms, use of resources forms, and patient diaries.
|
Both arms at the end of the intervention (12-month)
|
Change from Baseline in Diet intake scores from multiple 24-hour recalls, complemented by a Food Frequency Questionnaire (FFQ).
Time Frame: Both arms at the baseline and at the end of the intervention (12-month)
|
All patients will answer at the baseline and at the end of the intervention the FFQ.
All patients will answer at the baseline and at the end of the intervention the Food Frequency Questionnaire.
Data will be entered in to the FFQ European Prospective Investigation into Cancer and Nutrition (EPIC) Tool for Analysis (FETA).
FETA calculates the average daily intake of 46 nutrients and 14 food groups, for each individual.
The default nutrients list provides a description of each nutrient/food group and the units used.
The nutrient data for the FFQ foods have come from McCance and Widdowson's "The Composition of Foods (5th edition)" and its associated supplements.
|
Both arms at the baseline and at the end of the intervention (12-month)
|
Change from Baseline in Diet quality scores from The World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) standardised scoring system (Shams-White et al 2019).
Time Frame: Both arms at the baseline and at the end of the intervention (12-month)
|
All patients will answer at the baseline and at the end of the intervention the WCRF/AICR.
The higher the score, the better Diet quality.
|
Both arms at the baseline and at the end of the intervention (12-month)
|
Change from Baseline in BMI scores.
Time Frame: Both arms at the baseline and at the end of the intervention (12-month); intervention arm each 2 months
|
The dietitian will perform physical assessments of each patient at the baseline and at the end of the study.
Weight and height will be combined to report BMI in kg/m^2.
Patients in the intervention arm will self-report weight in kg every 2 months.
|
Both arms at the baseline and at the end of the intervention (12-month); intervention arm each 2 months
|
Change from Baseline in Lean Body Mass (LBM) scores.
Time Frame: Both arms at the baseline and at the end of the intervention (12-month)
|
The dietitian will perform physical assessments of each patient at the baseline and at the end of the study.
Weight and body fat will be combined to report LBM in kg*(Percentage body/100).
|
Both arms at the baseline and at the end of the intervention (12-month)
|
Change from Baseline in waist circumference scores.
Time Frame: Both arms at the baseline and at the end of the intervention (12-month)
|
The dietitian will perform physical assessments of each patient at the baseline and at the end of the study.
Waist circumference will be measured in cm.
|
Both arms at the baseline and at the end of the intervention (12-month)
|
Change from Baseline in Segmental Body Composition scores assessed measured by Body Composition Monitor bioimpedance spectroscopy (BIS).
Time Frame: Both arms at the baseline and at the end of the intervention (12-month).
|
The dietitian will perform physical assessments on each patient at the baseline and at the end of the study.
Weight (Kg) and body fat (%) and Total Body Water (TBW) will be combined to report the Body Composition score.
|
Both arms at the baseline and at the end of the intervention (12-month).
|
Change from Baseline in muscle strength scores on handgrip measurements.
Time Frame: Both arms at the baseline and at the end of the intervention (12-month)
|
The dietitian will perform physical assessments to each patient at the baseline and at the end of the study.
Muscle strength will be measured using hand grip strength (HGS) based on the Jamar Dynamometer (Model 091011725).
|
Both arms at the baseline and at the end of the intervention (12-month)
|
Change from Baseline in Nutritional risk scores assessed by the Malnutrition Screening Tool (MST). The higher the score, the higher risk of malnutrition.
Time Frame: Both arms at the baseline and at the end of the intervention (12-month)
|
All patients will complete the MST at the baseline and at the end of the intervention.
Patients in the intervention arm answer the MST each 2 months.
The higher the score, the higher risk of malnutrition.
|
Both arms at the baseline and at the end of the intervention (12-month)
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Chair: Kate O Connell, Ms., Research Support Officer Clinical (Nurse Manager)
- Study Chair: Laia Raigal, Dr., Data Manager
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Uterine Neoplasms
- Genital Neoplasms, Female
- Uterine Cervical Diseases
- Uterine Diseases
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Genital Diseases
- Genital Diseases, Female
- Uterine Cervical Neoplasms
- Endometrial Neoplasms
Other Study ID Numbers
- R19258
- WHI19CON (Other Grant/Funding Number: Irish Cancer Society)
- BCR-2019-09-ICS-UCC (Other Grant/Funding Number: Breakthrough Cancer Research)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cervical Cancer
-
University of California, San DiegoWithdrawnCervical Cancer | Cervical Cancer Stage | Cervical Cancer Stage IB2 | Cervical Cancer Stage IB1 | Cervical Cancer Stage I | Cervical Cancer Stage IB | Cervical Cancer Stage II | Cervical Cancer Stage IIa | Cervical Cancer, Stage IIB | Cervical Cancer, Stage III | Cervical Cancer Stage IIIB | Cervical Cancer... and other conditionsUnited States
-
M.D. Anderson Cancer CenterWithdrawnStage IB3 Cervical Cancer FIGO 2018 | Stage II Cervical Cancer FIGO 2018 | Stage IIA Cervical Cancer FIGO 2018 | Stage IIA1 Cervical Cancer FIGO 2018 | Stage IIA2 Cervical Cancer FIGO 2018 | Stage IIB Cervical Cancer FIGO 2018 | Stage III Cervical Cancer FIGO 2018 | Stage IIIA Cervical Cancer FIGO... and other conditions
-
Abramson Cancer Center of the University of PennsylvaniaWithdrawnCervical Cancer | Stage IB Cervical Cancer | Stage IIA Cervical Cancer | Stage IIB Cervical Cancer | Stage III Cervical Cancer | Stage IVA Cervical Cancer
-
National Cancer Institute (NCI)CompletedCervical Adenocarcinoma | Cervical Squamous Cell Carcinoma | Stage IB Cervical Cancer | Stage IIA Cervical Cancer | Stage IIB Cervical Cancer | Stage III Cervical Cancer | Stage IVA Cervical Cancer | Stage IVB Cervical CancerUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingStage IA Cervical Cancer | Stage IB Cervical Cancer | Stage IA1 Cervical Cancer | Stage IA2 Cervical Cancer | Stage IB1 Cervical Cancer | Stage IB2 Cervical Cancer | Stage IB3 Cervical CancerUnited States
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingCervical Adenosquamous Carcinoma | Cervical Squamous Cell Carcinoma, Not Otherwise Specified | Recurrent Cervical Carcinoma | Stage IB3 Cervical Cancer FIGO 2018 | Stage II Cervical Cancer FIGO 2018 | Stage IIA Cervical Cancer FIGO 2018 | Stage IIA1 Cervical Cancer FIGO 2018 | Stage IIA2 Cervical... and other conditionsUnited States
-
Shanghai First Maternity and Infant HospitalNot yet recruitingCervical Cancer, Stage IIB | Cervical Cancer Stage IIIB | Cervical Cancer Stage IIIA | Cervical Cancer, Stage IVA
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedCervical Adenocarcinoma | Cervical Squamous Cell Carcinoma | Stage IB Cervical Cancer | Stage IIA Cervical Cancer | Stage IIB Cervical Cancer | Stage III Cervical Cancer | Stage IVA Cervical CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)CompletedRecurrent Cervical Cancer | Stage IVA Cervical Cancer | Stage IVB Cervical Cancer | Stage IIIA Cervical Cancer | Stage IIIB Cervical CancerUnited States
-
Institut de Cancérologie de LorraineCompletedCervical Adenocarcinoma | Stage IB Cervical Cancer | Stage III Cervical Cancer | Stage II Cervical CancerFrance
Clinical Trials on Survivorship Clinic Assessments
-
University of California, San FranciscoSwim Across AmericaRecruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | Childhood CancerUnited States
-
UNC Lineberger Comprehensive Cancer CenterNational Cancer Institute (NCI)Completed
-
Debra FriedmanNational Cancer Institute (NCI)Active, not recruiting
-
Massachusetts General HospitalEnrolling by invitation
-
Columbia UniversitySusan G. Komen Breast Cancer FoundationCompleted
-
Jonsson Comprehensive Cancer CenterCompletedBreast CancerUnited States
-
Jewish General HospitalRecruiting
-
Washington University School of MedicineEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsActive, not recruitingHIV/AIDS | Sexually Transmitted InfectionsNigeria
-
Jamie StudtsUniversity of Louisville; Bristol-Myers Squibb Foundation; Lung Cancer AllianceCompletedLung CancerUnited States
-
Shaukat Khanum Memorial Cancer Hospital & Research...Enrolling by invitationSatisfaction, Patient | SatisfactionPakistan